Arturo Rodriguez Martin, MD
Family Medicine · Port Charlotte, FLNPI 1184605495
Payments from drug & device makers
Across 418 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$649
- Lilly USA, LLC$638
- Teva Pharmaceuticals USA, Inc.$487
- Novartis$434
- Sanofi-aventis U.S. LLC$391
- plus $4K from 31 others
What the payments were for
- Food & beverage$7,438100%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 79 | $1,242 |
| AstraZeneca | 38 | $649 |
| Lilly USA, LLC | 37 | $638 |
| Teva Pharmaceuticals USA, Inc. | 24 | $487 |
| Novartis | 23 | $434 |
| Sanofi-aventis U.S. LLC | 22 | $391 |
| AbbVie(2 entities) | 21 | $385 |
| GSK | 21 | $344 |
| Neurocrine Biosciences, Inc. | 9 | $303 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $277 |
| Amarin Pharma, Inc. | 15 | $235 |
| Boehringer Ingelheim | 12 | $216 |
| Merck | 12 | $208 |
| Pfizer | 12 | $192 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $169 |
| Amgen(2 entities) | 6 | $164 |
| Johnson & Johnson | 6 | $124 |
| Axsome Therapeutics, Inc. | 5 | $118 |
| Biogen | 6 | $114 |
| Esperion Therapeutics, Inc. | 5 | $92 |
| Dexcom, Inc. | 4 | $73 |
| Mylan Specialty L.p. | 3 | $65 |
| Kowa Pharmaceuticals America, Inc. | 4 | $63 |
| Bayer | 3 | $57 |
| Abbott | 3 | $55 |
| Eisai Inc. | 3 | $52 |
| Philips North America LLC | 2 | $52 |
| Biohaven Pharmaceuticals, Inc. | 2 | $47 |
| Nestle Healthcare Nutrition Inc. | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Aimmune Therapeutics, Inc. | 2 | $31 |
| Exact Sciences | 1 | $24 |
| Optinose US, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $19 |
| Organogenesis Inc. | 2 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Kvk-tech, Inc. | 1 | $14 |
How this compares
$7,466 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 202 | $272,141 |
| AustedoDeutetrabenazine | 34 | $204,577 |
| EliquisApixaban | 151 | $124,234 |
| MounjaroTirzepatide | 95 | $109,668 |
| JardianceEmpagliflozin | 67 | $87,798 |
| FarxigaDapagliflozin Propanediol | 48 | $44,526 |
| RybelsusSemaglutide | 32 | $44,513 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 59 | $42,049 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 37 | $37,446 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $36,825 |
| TrulicityDulaglutide | 29 | $35,954 |
| VascepaIcosapent Ethyl | 66 | $34,408 |
| XareltoRivaroxaban | 22 | $28,318 |
| LinzessLinaclotide | 31 | $27,923 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $27,794 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,242 | $316,653234 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $487 | $204,57734 claims |
| Lilly USA, LLCMounjaro, Trulicity | $638 | $145,622124 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $216 | $125,243104 claims |
| PfizerEliquis | $192 | $124,234151 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $649 | $86,575107 claims |
| AbbVieLinzess, Ubrelvy, Vraylar, Synthroid | $385 | $67,820115 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $344 | $42,55863 claims |
| Johnson & JohnsonXarelto | $124 | $28,31822 claims |
| NovartisEntresto | $434 | $22,34831 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $391 | $22,20313 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $169 | $19,80537 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Port Charlotte
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.